The Multiple Sclerosis Functional Composite A clinically meaningful measure of disability

被引:121
作者
Polman, Chris H. [1 ]
Rudick, Richard A. [2 ]
机构
[1] Vrije Univ Amsterdam Med Ctr, Free Univ Hosp, Dept Neurol, NL-1007 MB Amsterdam, Netherlands
[2] Cleveland Clin, Mellen Ctr Multiple Sclerosis Treatment & Res, Cleveland, OH 44106 USA
关键词
MAGNETIZATION-TRANSFER RATIO; APPEARING WHITE-MATTER; QUALITY-OF-LIFE; REFERENCE POPULATION; OUTCOMES ASSESSMENT; INTERFERON BETA-1A; STATUS SCALE; MS; PROGRESSION; GREY;
D O I
10.1212/WNL.0b013e3181dbb571
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Background: The Multiple Sclerosis Functional Composite (MSFC) provides a focused and sensitive evaluation of disability in patients with multiple sclerosis ( MS) that may be more responsive to change than that provided by the Expanded Disability Status Scale. Expert Clinical Opinion: The MSFC is a 3-part quantitative instrument that measures arm, leg, and cognitive function with the 9-Hole Peg Test (arm/hand dexterity), the Timed 25-Foot Walk ( leg function), and the Paced Auditory Serial Addition Test (3-second version, PASAT3; cognition). The MSFC has excellent test-retest reliability. Construct validity was supported by expected differences in scores between patients with primary or secondary progressive MS compared with relapsing-remitting MS. Concurrent validity was demonstrated by significant correlations with the Expanded Disability Status Scale, the Sickness Impact Profile, and the Short Form-36, particularly on the physical components of the latter 2 scales. MSFC scores also correlate with MRI changes. Limitations of the MSFC include practice effects with the PASAT and to a lesser extent the 9-Hole Peg Test, variations in the reference populations used to calculate Z-scores, and the lack of an accepted definition of a clinically meaningful change. Future Directions: Future research should be directed at adding a test that measures visual function ( e. g., contrast acuity), at replacing the PASAT by a cognition test that has better measurement characteristics, and at developing methods to better understand the clinical relevance of changes in MSFC scores. NEUROLOGY 2010; 74(Suppl 3): S8-S15
引用
收藏
页码:S8 / S15
页数:8
相关论文
共 55 条
[1]   Brain metabolite changes in cortical grey and normal-appearing white matter in clinically early relapsing-remitting multiple sclerosis [J].
Chard, DT ;
Griffin, CM ;
McLean, MA ;
Kapeller, P ;
Kapoor, R ;
Thompson, AJ ;
Miller, DH .
BRAIN, 2002, 125 :2342-2352
[2]   Intrarater and interrater reliability of the MS functional composite outcome measure [J].
Cohen, JA ;
Fischer, JS ;
Bolibrush, DM ;
Jak, AJ ;
Kniker, JE ;
Mertz, LA ;
Skaramagas, TT ;
Cutter, GR .
NEUROLOGY, 2000, 54 (04) :802-806
[3]   Benefit of interferon β-1a on MSFC progression in secondary progressive MS [J].
Cohen, JA ;
Cutter, GR ;
Fischer, JS ;
Goodman, AD ;
Heidenreich, FR ;
Kooijmans, MF ;
Sandrock, AW ;
Rudick, RA ;
Simon, JH ;
Simonian, NA ;
Tsao, EC ;
Whitaker, JN .
NEUROLOGY, 2002, 59 (05) :679-687
[4]   Use of the Multiple Sclerosis Functional Composite as an outcome measure in a phase 3 clinical trial [J].
Cohen, JA ;
Cutter, GR ;
Fischer, JS ;
Goodman, AD ;
Heidenreich, FR ;
Jak, AJ ;
Kniker, JE ;
Kooijmans, MF ;
Lull, JM ;
Sandrock, AW ;
Simon, JH ;
Simonian, NA ;
Whitaker, JN .
ARCHIVES OF NEUROLOGY, 2001, 58 (06) :961-967
[5]   Development of a multiple sclerosis functional composite as a clinical trial outcome measure [J].
Cutter, GR ;
Baier, ML ;
Rudick, RA ;
Cookfair, DL ;
Fischer, JS ;
Petkau, J ;
Syndulko, K ;
Weinshenker, BG ;
Antel, JP ;
Confavreux, C ;
Ellison, GW ;
Lublin, F ;
Miller, AE ;
Rao, SM ;
Reingold, S ;
Thompson, A ;
Willoughby, E .
BRAIN, 1999, 122 :871-882
[6]   INTERFERON BETA-1B IS EFFECTIVE IN RELAPSING-REMITTING MULTIPLE-SCLEROSIS - CLINICAL-RESULTS OF A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL [J].
DUQUETTE, P ;
GIRARD, M ;
DESPAULT, L ;
DUBOIS, R ;
KNOBLER, RL ;
LUBLIN, FD ;
KELLEY, L ;
FRANCIS, GS ;
LAPIERRE, Y ;
ANTEL, J ;
FREEDMAN, M ;
HUM, S ;
GREENSTEIN, JI ;
MISHRA, B ;
MULDOON, J ;
WHITAKER, JN ;
EVANS, BK ;
LAYTON, B ;
SIBLEY, WA ;
LAGUNA, J ;
KRIKAWA, J ;
PATY, DW ;
OGER, JJ ;
KASTRUKOFF, LF ;
MOORE, GRW ;
HASHIMOTO, SA ;
MORRISON, W ;
NELSON, J ;
GOODIN, DS ;
MASSA, SM ;
GUTTERIDGE, E ;
ARNASON, BGW ;
NORONHA, A ;
REDER, AT ;
MARTIA, R ;
EBERS, GC ;
RICE, GPA ;
LESAUX, J ;
JOHNSON, KP ;
PANITCH, HS ;
BEVER, CT ;
CONWAY, K ;
WALLENBERG, JC ;
BEDELL, L ;
VANDENNOORT, S ;
WEINSHENKER, B ;
WEISS, W ;
REINGOLD, S ;
PACHNER, A ;
TAYLOR, W .
NEUROLOGY, 1993, 43 (04) :655-661
[7]   Randomised double-blind placebo-controlled study of interferon β-1a in relapsing/remitting multiple sclerosis [J].
Ebers, GC ;
Rice, G ;
Lesaux, J ;
Paty, D ;
Oger, J ;
Li, DKB ;
Beall, S ;
Devonshire, V ;
Hashimoto, S ;
Hooge, J ;
Kastrukoff, L ;
Krieger, C ;
Mezei, M ;
Seland, P ;
Vorobeychi, G ;
Morrison, W ;
Nelson, J ;
Freedman, MS ;
Chrisie, S ;
Nelson, R ;
Rabinovitch, H ;
Freedman, C ;
Hartung, HP ;
Rieckmann, P ;
Archelos, J ;
Jung, S ;
Weilbach, F ;
Flachenecke, P ;
Sauer, J ;
Hommes, O ;
Jongen, P ;
Brouwer, S ;
McLeod, J ;
Pollard, J ;
Ng, R ;
Sandberg-Wollheim, M ;
Källén, K ;
Nilsson, P ;
Ekberg, R ;
Lundgren, A ;
Jadbäck, G ;
Wikström, J ;
Multanen, J ;
Valjakka, M ;
Carton, H ;
Lissoir, F ;
Declerq, I ;
Vieren, M ;
Peeters, E ;
Dubois, B .
LANCET, 1998, 352 (9139) :1498-1504
[8]  
Fischer J.S., 2001, Multiple sclerosis functional composite: Administration and scoring manual
[9]   The Multiple Sclerosis Functional Composite measure (MSFC): an integrated approach to MS clinical outcome assessment [J].
Fischer, JS ;
Rudick, RA ;
Cutter, GR ;
Reingold, SC .
MULTIPLE SCLEROSIS JOURNAL, 1999, 5 (04) :244-250
[10]  
Fischer JS, 2000, ANN NEUROL, V48, P885, DOI 10.1002/1531-8249(200012)48:6<885::AID-ANA9>3.0.CO